The global impact of Precision Medicine Group.
As it happens.
Impact, observations, and insights on the evolving healthcare landscape.
BETHESDA, MD., September 16, 2025 — Precision Medicine Group (Precision), a leading provider of next-generation drug development, CRO and commercialization services, today announced the appointment of Tracey Leahy as the company’s Chief People Officer (CPO), effective immediately. Ms. Leahy will be aligning workforce strategies with business goals and is responsible for all aspects of Precision’s Human Resources (HR) function, including talent acquisition and management, total rewards, learning and development, and HR operations. (more…)
Precision Medicine Group Names Pharma Services Innovator, Eric Hodgins, as Chief Information and Technology Officer
Industry veteran with a 30-year track record in building award-winning clinical and commercial technologies, Hodgins will focus on developing and enriching transformative technologies across Precision’s R&D and commercial services
BETHESDA, Md., April 16, 2025 – Precision Medicine Group (Precision), a leading provider of next-generation drug development, CRO and commercialization services, today announced the appointment of Eric Hodgins as the company’s Chief Information and Technology Officer, overseeing all of the company’s technology assets. (more…)
Karl Deonanan appointed Chief Financial Officer
Matt DeZee named to newly established role, Chief Transformation and Strategy Officer
Bethesda, Md., October 23, 2024—Precision Medicine Group (Precision), a leading next-generation provider of drug development and commercialization services, today announced key leadership changes to support its next phase of growth. This includes the appointment of Karl Deonanan as Chief Financial Officer (CFO). Mr. Deonanan succeeds Matt DeZee, who has served as CFO of Precision since 2020 and will be transitioning to the newly created role of Chief Transformation and Strategy Officer (CTSO), effective immediately.
— Founding CEO Mark Clein named Executive Chairman; Mr. Clein and co-founder Ethan Leder to continue as Board Directors —
BETHESDA, MD., October 1, 2024 – Precision Medicine Group (Precision), a leading next-generation provider of drug development and commercialization services, today announced the appointment of Margaret Keegan as Chief Executive Officer (CEO) and member of the Board of Directors, effective immediately. Ms. Keegan succeeds Mark Clein, who is assuming the role of Executive Chairman. Mr. Clein co-founded Precision in 2012 as CEO and, together with co-founder Ethan Leder, purpose-built Precision to capitalize on the scientific and technological innovations that are transforming drug development and enabling widespread access to new, breakthrough therapies. Mr. Leder formerly served as Executive Chairman and will remain a member of the Board of Directors.
Precision for Medicine, a leading biomarker-driven clinical research organization (CRO), received wide recognition at the prestigious 2023 CRO Leadership Awards. The awards acknowledge top CRO partners and are determined by feedback from pharma and biotech sponsors. Precision has been honored in all five categories: Capabilities, Compatibility, Expertise, Quality, and Reliability, securing awards in the Overall, Big Pharma, and Small Pharma categories, along with several distinguished Champion Awards.
This recognition serves as a testament to our commitment to quality and our clients’ trust in delivering measurable results.
Bethesda, Md., April 12, 2023 — Precision Value & Health, the industry leader in delivering complementary, integrated and specialized capabilities across the commercialization continuum, today announced that it has acquired Makara Health, a UK-based international healthcare communications agency. The move will expand Precision’s European footprint and reinforce the company’s market growth position with its core capabilities in Europe. Founded in 2013, Makara has capabilities in learning and development, medical and patient education, PR and brand promotion, offering its diverse roster of healthcare client companies high-quality, strategic, scientifically robust programs, as well as creative delivery solutions.
With this acquisition, Makara becomes part of the Precision Value & Health team. The Makara team will work closely with PRECISIONscientia, an agency dedicated to delivering medical and scientific communications that expertly interpret and translate the science of medicine.
Houston is one of seven global Precision specialty labs addressing the rising demand for rapid, comprehensive biomarker data to support the development of advanced therapies and diagnostics
HOUSTON, Tx., April 12, 2023 – Precision for Medicine, the first global biomarker-driven clinical research organization, today announced the expansion of its cell biology and genomics laboratory in Houston, TX, proliferating the company’s global biomarker capabilities and laboratory operations.
BETHESDA, MD, March 14, 2023 – Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services, today announced the appointment of John Hubbard, PhD, as Chairman of its Board of Directors.
“We are thrilled to welcome John to our Board. He is a highly regarded leader in the pharmaceutical industry with extensive experience in clinical development and operations, strategic planning and business development,” said Mark Clein, Chief Executive Officer of Precision Medicine Group. “His impressive qualifications make him uniquely qualified to appreciate the breadth of services offered across our organization and to provide valuable insight as we continue to expand our global footprint and integrated capabilities.”
PARIS, FRANCE – 10 November 2022 — Precision for Medicine, the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively, today announced that it has received updated CIR accreditation from the French Ministry of Higher Education and Research.
The French R&D tax credit initiative (‘Crédit d’Impôt Recherche’, CIR) gives eligible research-based French companies, who are subject to corporate tax in France, the ability to claim tax relief on costs generated in R&D activities outsourced to Precision for Medicine.
Under this accreditation, the French Ministry of Higher Education and Research has also recognized Precision for Medicine’s Italian, German, Polish, Spanish, and Hungarian affiliates as reputable cross-border R&D experts.
Andrea Cotton-Berry, Precision for Medicine’s Global Head of Strategic Development, commented: “We are thrilled to receive this accreditation as it allows our current and future clients in France to benefit from a tax relief of up to 30% of their R&D expenditure committed to Precision for Medicine.”
About Precision for Medicine
Precision for Medicine supports life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research that take advantage of the latest advancements in science and technology, focusing predominantly on genomics, immune-response assays, global specimen logistics, biomarker analytics, companion diagnostics, and clinical trial execution. Precision for Medicine is part of Precision Medicine Group, with over 3,000 employees in 40 locations across North America, Europe and APAC. For more information, visit precisionformedicine.com.
# # #
Contact:
Estelle Roger, Precision Medicine Group Senior Program Manager
estelle.roger@precisionmedicinegrp.com
QuartzBio’s suite of end-to-end SaaS solutions provides pharmaceutical and biotech clients with a fully connected data ecosystem linking sample, biomarker, and clinical data to improve collaboration, planning and R&D productivity.
[Frederick, MD – January 24, 2023] Precision for Medicine, the first global, precision medicine clinical research services organization, today announced the strategic acquisition of SolveBio by QuartzBio.
SolveBio’s intelligent technologies and enterprise data management platform has integrated into QuartzBio’s suite of SaaS solutions, providing a single, scalable solution supporting clinical sample inventory management and biomarker data management for the biotech and pharmaceutical sectors.